Nemea (Clozapine)

Clozapine, the active ingredient in Nemea, is an atypical antipsychotic presented as a unknown/unknown for oral use. It treats schizophrenia, treatment‑resistant schizophrenia and schizoaffective disorder in adults, helping to reduce psychotic symptoms and improve overall functioning.

GNH USA supplies Nemea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clozapine is an atypical antipsychotic used for several serious psychiatric conditions.

Schizophrenia: reduces psychotic symptoms and improves functional outcomes in patients with schizophrenia. Treatment‑Resistant Schizophrenia: provides symptom control when other antipsychotics have failed. Schizoaffective Disorder: helps manage both mood and psychotic components of the disorder.

Clozapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Weight gain - Constipation - Excessive salivation - Orthostatic hypotension - Tachycardia

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white‑blood‑cell count) - Myocarditis or cardiomyopathy - Seizures, especially at higher doses - Metabolic disturbances such as hyperglycaemia

Clozapine requires careful monitoring and patient education before and during therapy.

Baseline blood count: obtain a complete blood count before initiating treatment. Regular hematology monitoring: perform weekly CBC for the first 6 months, then bi‑weekly to monthly as advised. Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal risk. Monitor for metabolic changes: check weight, glucose and lipid levels periodically. Store at ambient temperature: keep in original container, protect from moisture and heat.

Clozapine can interact with several drug classes, affecting its safety and efficacy.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): may increase clozapine plasma levels. - CNS depressants (e.g., benzodiazepines, opioids): heightened sedation and respiratory depression risk. - Myelosuppressive agents: additive risk of agranulocytosis.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce clozapine concentrations. - Anticholinergic drugs: may worsen constipation. - Antihypertensives: additive orthostatic hypotension.